📊 $VKTX Technical Update 💰 $25.17 | 🩸 Bearish ⚡ ATR: ±$2.08 📐 WEINSTEIN STAGE ANALYSIS: 🔵 WEEKLY (3Y): STAGE 1 · BASE (35% conf) 🔴 DAILY (1Y): STAGE 4 · DOWNTREND ▼ AVOID (95% conf) 📉 RS ANALYSIS: - vs SPY: -25.5% (Underperforming) - vs XBI: -14.7% (Underperforming Sector) 💧 Institutional Flow: STRONG DISTRIBUTION ▼ 🔹 WEEKLY (3Y): RSI: 39.9 | Below Cloud S: $25.22 R: $34.02 🔹 DAILY (1Y): RSI: 35.9 | Below Cloud S: $21.62 R: $34.02 🚫 AVOID: DAILY (1Y) 🧠 Strategic Breakdown: Maximum Daily Stage 4 Breakdown Undercutting $25.22 Base Support The updated Seahorse metrics for $VKTX (Viking Therapeutics, Inc.) reflect a severe short-term breakdown, with price dropping to $25.17...undercutting its critical $25.22 Weekly Base Support level while locked in a high-conviction 95% Daily Stage 4 Markdown. Maximum Confidence Daily Stage 4 Markdown vs. Decaying Weekly Base: Daily Timeframe (1Y): The short-term chart is trapped in a maximum 95% confident Stage 4 Downtrend. Trading Below the Daily Cloud with a weak 35.9 Daily RSI reflects persistent short-term selling pressure and zero dynamic support. Weekly Timeframe (3Y): The multi-year framework holds a 35% confident Stage 1 Base tag, but price trading at $25.17 is now actively violating the $25.22 Weekly Support floor. A weekly closing bar below $25.22 will break the Stage 1 base structure and trigger a macro Stage 4 markdown downgrade. Severe Relative Weakness & Distribution Pressure: Sector & Market Underperformance: Relative strength against SPY sits at -25.5%, while relative performance against the biotech sector ETF (XBI) stands at -14.7%, confirming that $VKTX is lagging both the broader market and its industry peers. Flow Invariant: Strong Distribution confirms large institutional holders continue to unload shares on any attempt at a bounce, swamping retail demand. VK2735 & VK2809 Pipeline Context vs. Valuation Compression: Obesity & MASH Pipeline Execution: While data for VK2735 (dual GLP-1/GIP agonist) and VK2809 remain long-term clinical value drivers, broader biopharma profit-taking and competitive GLP-1 pricing dynamics continue to force multi-quarter valuation compression across non-commercial biotech names. Tactical Execution Parameters: Primary Overhead Resistance Ceiling: $34.02 (Confluence of Daily & Weekly Resistance) — Major supply wall marking the top of the Daily Cloud and moving average supply. Immediate Downside Risk Level: $21.62 (Daily Support Floor) — The lower line of defense if $25.22 fails to hold on a weekly close. Macro Breakdown Threshold: $25.22 (Weekly Base Floor) — Must be reclaimed immediately on a weekly close to keep the Stage 1 base thesis alive. The Play: Strictly enforce the 🚫 AVOID: DAILY (1Y) mandate. Do not attempt to catch falling knives or front-run a base bottom while Strong Distribution dominates and price trades Below the Daily Cloud. Wait for $VKTX to stabilize above $25.22 and build a confirmed Daily Stage 1 base before considering long re-entry setups.